In knock­out IPO of­fer­ings, Mor­phoSys and Sur­face On­col­o­gy haul com­bined $316M in up­sized deals

Two biotechs new to Nas­daq sparked more in­vestor in­ter­est than orig­i­nal­ly ex­pect­ed Wednes­day, haul­ing up­sized IPOs that are yet an­oth­er in­di­ca­tion of the in­dus­try’s rip-roar­ing state.

In one of the chunki­er IPOs this year, Ger­many’s Mor­phoSys $MOR raised up­wards of $207.8 mil­lion. That’s near­ly $58 mil­lion more than the com­pa­ny’s ear­ly ex­pec­ta­tions. The com­pa­ny, which is al­so list­ed on a Ger­man ex­change, says it’s gath­er­ing re­sources to sink $225 mil­lion in­to the de­vel­op­ment of its in­ves­ti­ga­tion­al an­ti-CD19 an­ti­body MOR208.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER